1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

TABLE 1: Clinical data of GDC treatment cases with thrombus forming at coil-parent artery interface
Case no. Age (yr) Sex Location Aneurysm Diameter (mm) Aneurysm Neck (mm) Ruptured Procedural Therapy Follow-up Therapy^* Evidence of Stroke at Discharge
1 54 F Ophthalmic 6 × 3 5 No Abciximab Aspirin, Plavix No
2 67 F Basilar tip 5 3.5 No Abciximab Aspirin No
3 55 F Basilar tip 8 3.5 No Abciximab Aspirin, Plavix No
4 45 M Basilar tip 6 × 8 5 Yes Heparin Aspirin No
5 49 M Basilar tip 6 5 Yes Heparin Aspirin No
6 43 M Posterior communicating 12 × 20 5 Yes Heparin Aspirin No
7 39 M Posterior communicating 6 × 8 5 Yes Heparin Aspirin No
8 57 F Superior hypophyseal 10 6 No Integrilin and heparin Aspirin No
9 49 F Superior hypophyseal 12 8 No Abciximab Aspirin,Plavix No
Note.—F indicates female; M, male.
* Aspirin, 325 mg/day; Plavix, 75 mg/day with 300 mg loading dose on day 1.